22:15 , Aug 2, 2018 |  BC Innovations  |  Tools & Techniques

Model firsts

By combining disparate data into coherent mechanistic models, quantitative systems pharmacology is becoming a key tool for picking the right dose for first-in-human trials and other early make-or-break decisions. Advocates see it as part of...
07:00 , Apr 14, 2016 |  BC Innovations  |  Strategy

Next stop: Houston

Last month's opening by Johnson & Johnson of the Houston-based JLABS incubator is being seen as a coup by local leaders hoping to make the city the "third coast" of biotech. But stakeholders inside and...
07:00 , Sep 4, 2014 |  BC Innovations  |  Targets & Mechanisms

Destabilizing data in CF

Two independent labs have produced in vitro evidence that combining Kalydeco ivacaftor with lumacaftor destabilizes the compounds' cystic fibrosis transmembrane conductance regulator target 1,2 -contradicting the positive data from Vertex Pharmaceuticals Inc. 's recent Phase...
07:00 , Jun 22, 2009 |  BioCentury  |  Emerging Company Profile

Beactica: More Efficient Resonance

Surface plasmon resonance, or SPR, is used in fragment-based drug discovery because it provides a wealth of information about how a compound or fragment interacts with its target. Beactica AB is seeking to improve the...
08:00 , Jan 19, 2009 |  BC Week In Review  |  Company News

Beactica, General Electric, Uppsala University deal

General Electric's GE Healthcare unit, Beactica and the university will develop the next generation of GE's Biacore surface plasmon resonance instruments and applications for fragment-based drug discovery. The collaboration also will use the technology to...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Company News

Trega Biosciences Inc. board of directors update

Trega Biosciences Inc. (TRGA), San Diego, Calif.   Business: Drug discovery   Appointed: Jeremy Levin, CEO, president and chairman of Cadus Pharmaceutical Corp. (KDUS, Tarrytown, N.Y.); and Anders Wiklund, SVP of Biacore Holding Inc., an...
07:00 , Sep 15, 2008 |  BioCentury  |  Emerging Company Profile

Heptares: Stabilizing GPCR discovery

Structure-based drug design is increasingly used to discover therapeutics against soluble protein targets such as kinases and proteases, but has not traditionally been used for GPCRs, the most common family of drug targets, because they...
08:00 , Feb 4, 2008 |  BC Week In Review  |  Company News

Genetix Group management update

Genetix Group plc (LSE:GTX), New Milton, U.K.   Business: Supply/Service, Genomics, Proteomics   Hired: Jerry Williamson as president of U.S. operations, formerly president of General Electric Co .’s Biacore Inc. unit  ...
08:00 , Nov 5, 2007 |  BC Week In Review  |  Company News

Affibody management update

Affibody AB , Stockholm, Sweden   Business: Proteomics   Hired: Erik Wallden as CEO, formerly president and CEO of Biacore AB; he succeeds Ulf Boberg, who will remain as SVP of clinical development and business...
07:00 , Jun 25, 2007 |  BC Week In Review  |  Company News

VisEn Medical management update

VisEn Medical Inc. , Woburn, Mass.   Business: Diagnostic   Hired: Jerry Williamson as EVP and CCO, formerly president of General Electric Co. 's Biacore Inc. unit  ...